Synonyms: PF-5190457
Compound class:
Synthetic organic
Comment: PF-05190457 is a selective, orally bioavailable and competitive antagonist of the ghrelin receptor [1], with potential therapeutic utility for the treatment of obesity and type 2 diabetes [2], and for treating alcohol use disorder.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
PF-05190457 was advanced to clinical evaluation in several early stage trials. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01247896 | Single Dose Escalation Study of PF-05190457 in Healthy Volunteers | Phase 1 Interventional | Pfizer | ||
NCT02039349 | A Novel Compound for Alcoholism Treatment | Phase 1 Interventional | National Institutes of Health Clinical Center (CC) | ||
NCT02707055 | A Novel Compound for Alcoholism Treatment: A Translational Strategy - Part II | Phase 2 Interventional | National Institutes of Health Clinical Center (CC) |